Mergers & Acquisitions - Biotechnology, Mergers & Acquisitions

Filter

Popular Filters

1 to 25 of 273 results

Kite Pharma acquires T-Cell Factory for $21 million upfront

19-03-2015

US oncology biopharma specialist Kite Pharma has further strengthened its TCR product platform and established…

BiotechnologyKite PharmaMergers & AcquisitionsT-Cell Factory

Pharma and biotech M&A deals reached record $212 billion in 2014

Pharma and biotech M&A deals reached record $212 billion in 2014

19-03-2015

Despite a slight wobble in the spring, the pharma and biotech sector came back stronger than ever in…

BiotechnologyFinancialGlobalMergers & AcquisitionsPharmaceutical

Genmab acquires antibody assets from iDD Biotech

18-03-2015

Danish biotech company Genmab has entered into an agreement to purchase antibodies and related patents…

BiotechnologyGenmabiDD BiotechMergers & AcquisitionsOncology

UPDATE: Ignyta acquires four oncology R&D assets from Teva

UPDATE: Ignyta acquires four oncology R&D assets from Teva

18-03-2015

Israel-based generics giant Teva Pharmaceutical Industries says that US oncology focussed biotech firm…

BiotechnologyIgnytaMergers & AcquisitionsOncologyTeva Pharmaceutcal Industries

Ruthigen and Pulmatrix agree to merge

16-03-2015

US biopharma company Ruthigen has entered into a definitive merger agreement with Pulmatrix, clinical…

BiotechnologyMergers & AcquisitionsPulmatrixRespiratory and PulmonaryRuthigen

Pharmacyclics acquisition strengthens AbbVie pipeline, says Kalorama

13-03-2015

US pharma company AbbVie's recent acquisition of Pharmacyclics for $21 billion strengthens AbbVie's…

AbbVieBiotechnologyHematologyImbruvicaMergers & AcquisitionsOncologyPharmacyclics

Ember Therapeutics to merge with Mariel Therapeutics

Ember Therapeutics to merge with Mariel Therapeutics

12-03-2015

Ember Therapeutics, a US biotech company focused on obesity and diabetes therapies, is to merge with…

BiotechnologyEmber TherapeuticsMariel TherapeuticsMergers & AcquisitionsUSA

Targacept and Catalyst Biosciences agree to merge

Targacept and Catalyst Biosciences agree to merge

07-03-2015

Targacept and fellow USA-based Catalyst Biosciences, a privately held biopharmaceutical firm, have entered…

BiotechnologyCatalyst BiosciencesHematologyMergers & AcquisitionsTargacept

AbbVie acquisition of Pharmacyclics will help secure future cash flows as Humira biosimilars loom, says analyst

06-03-2015

US drugmaker AbbVie’s acquisition of Pharmacyclics, valued at $21 billion, will help the company alleviate…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyHematologyHumiraImbruvicaMergers & AcquisitionsOncologyPharmacyclics

AbbVie to acquire Pharmacyclics, aiming to create leading hematological oncology franchise

AbbVie to acquire Pharmacyclics, aiming to create leading hematological oncology franchise

05-03-2015

US drugmaker AbbVie revealed late yesterday that it has reached an agreement to acquire US biopharma…

AbbVieBiotechnologyHematologyImbruvicaJohnson & JohnsonMergers & AcquisitionsNovartisOncologyPharmacyclics

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

24-02-2015

In a second acquisition this year, Ireland-headquartered Shire revealed today that it has taken control…

BiotechnologyGastro-intestinalsMergers & AcquisitionsMeritage PharmaRare diseasesShire

Ipsen pays 6 million euros for option to acquire Canbex

24-02-2015

French drugmaker Ipsen today announced that UK-based biotech firm Canbex Therapeutics has granted an…

BiotechnologyCanbex TherapeuticsIpsenMergers & AcquisitionsNeurologicalVSN16R

Sosei acquires Heptares Therapeutics for up to $400 million

Sosei acquires Heptares Therapeutics for up to $400 million

23-02-2015

Japanese drugmaker Sosei Group says it has acquired Heptares Therapeutics, a clinical-stage private UK-based…

BiotechnologyHeptares TherapeuticsMergers & AcquisitionsNeurologicalRare diseasesSosei

Intrexon to acquire Belgium's ActoGeniX, bringing new generation of orally-delivered biotherapeutics

13-02-2015

US synthetic biology focussed US firm Intrexon has entered into a definitive agreement to acquire ActoGeniX,…

ActoGeniXBiotechnologyIntrexonMergers & Acquisitions

No new bidders emerge for Dendreon, so Valeant gets Provenge

No new bidders emerge for Dendreon, so Valeant gets Provenge

11-02-2015

US biotech firm Dendreon revealed yesterday that the bid deadline provided by the Court-approved bidding…

BiotechnologyDendreonMergers & AcquisitionsOncologyProvengeValeant Pharmaceuticals International

New biotech start-up OptiKira created by BioMotiv

New biotech start-up OptiKira created by BioMotiv

02-02-2015

USA-based BioMotiv, a drug development accelerator associated with The Harrington Project, the University…

BioMotivBiotechnologyDiabetesMergers & AcquisitionsOptiKiraRare diseasesResearch

Valeant to serve as “stalking horse bidder” in court-supervised Dendreon sales process

30-01-2015

US biotech firm Dendreon says it has reached an agreement with Canada’s Valeant Pharmaceuticals International…

BiotechnologyDendreonMergers & AcquisitionsOncologyProvengeValeant Pharmaceuticals International

RegeneRx links with G-treeBNT to develop RGN-259 in the USA

RegeneRx links with G-treeBNT to develop RGN-259 in the USA

29-01-2015

US biotech firm RegeneRx Biopharmaceuticals has entered into agreements with South Korea-based G-treeBNT…

BiotechnologyG-treeBNTLicensingMergers & AcquisitionsOphthalmicsRegeneRxRGN-259USA

Dendreon extends deadline for qualified bids for the company

Dendreon extends deadline for qualified bids for the company

28-01-2015

US biotech firm Dendreon said yesterday that it would be extending the bid deadline for interested parties…

BiotechnologyDendreonMergers & AcquisitionsOncologyProvenge

3SBio acquires Italy’s Sirton Pharmaceuticals

27-01-2015

Chinese biotech firm 3SBio today revealed that last month it acquired the entire share capital of Italy-based…

3SBioBiotechnologyEuropeMergers & AcquisitionsSirton Pharmaceuticals

Innovation and confidence at JP Morgan conference, says Edison analyst

26-01-2015

The atmosphere at this year's annual JPMorgan Conference in San Francisco was understandably buoyant,…

BiotechnologyFinancialMergers & AcquisitionsResearch

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

19-01-2015

Motif Biosciences, a partner of life science business developer Amphion Innovations, has entered into…

Amphion InnovationsAntibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsMotif BiosciencesMRSA antibioticUSA

Roche continues spending spree, with acquisition of French biotech firm Trophos

Roche continues spending spree, with acquisition of French biotech firm Trophos

16-01-2015

Continuing its recent spate of deal-making, Swiss pharma giant Roche has agreed to acquire Trophos, a…

BiotechnologyMergers & AcquisitionsolesoximeRare diseasesRocheSwitzerlandTrophos

Low dollar tipped to stimulate biotech investment in Australia

15-01-2015

Analyst commentary suggests the devaluation of the Australian dollar during 2014, has left biotech in…

ActinogenAustraliaBenitec BiopharmaBiotechnologyFinancialMergers & AcquisitionsSirtex Medical

1 to 25 of 273 results

Back to top